Firefly Bio

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

News

Freenome raises $254m for cancer tests, and other financings

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks